Insider buying last 90 days
No open-market insider purchases were filed for ICUI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
ICU Medical's stock rose this week after third-quarter results showed revenue increasing to $556 million, up 4% on an adjusted basis with 5% organic growth, driven by strength in Infusion Systems and Consumables. Adjusted earnings per share reached $2.44, up from $2.03 a year ago, and the company maintained its 2026 outlook, now expecting to land at the higher end of its previously issued adjusted EBITDA and EPS guidance ranges. Management also repaid $80 million in debt, bringing net leverage below 2 times, and is scheduled to present at the Jefferies Global Healthcare Conference in London on 18 November.
ICUI closed at $178.85, up 3.9%, sitting above both its 50-day average of $162.98 and 200-day average of $149.02, with the shorter average above the longer one. The GekkoIndex reads 46.2, placing the stock in the Neutral zone, down from a higher reading five days prior. Price sits 23.6% above Gekko Fair Value of $144.72, a gap that stands out against the otherwise constructive trend picture.
The next earnings date falls on 18 February 2027, well outside a typical 20-trading-day holding window, with the prior report having produced a 10.9% reaction and an average absolute reaction of 9.3% across the last eight quarters, all of which beat estimates. No insider, Congress or unusual options activity appears in their respective windows. Seasonally, the next 20 trading days have averaged a 1.7% gain over four years, rising in three of them, while three analyst firms currently carry buy ratings with a consensus target of $193.38.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
ICU Medical scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Above 50 and 200-day
Close $179.27 is above the 50-day ($163.72) and 200-day ($149.60) averages, and the 50-day is above the 200-day.
See the chart48, Neutral
Reading 48 is in the Neutral zone.
See the GekkoIndex21.3% above
Price is 21.3% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings+2.1% on average
From this point in the calendar, the next 20 trading days averaged +2.1% over 4 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
ICU Medical closed at $179.27 on Nov 13, 2026, +28.8% over the past year, inside a 52-week range of $113.37 to $192.85.
Use the left and right arrow keys to read daily values.
Put ICUI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
ICU Medical designs, manufactures and sells medical devices used in infusion therapy and critical care, working through subsidiaries around the world. Its offerings span needlefree connectors, catheter maintenance and disinfection tools, hemodialysis accessories, and systems for safely handling hazardous drugs during compounding. The company is also known for its intravenous fluids and irrigation solutions, its infusion pumps such as Plum 360 and LifeCare PCA, and software that links smart pumps to hospital records, asset tracking and alarm systems.
Beyond infusion products, ICU Medical supplies equipment for critical care settings, including hemodynamic monitoring systems, cardiac output and oximetry catheters, blood pressure transducers, and closed blood sampling systems. Alongside its devices, it offers related professional services. Its customers include acute care hospitals, wholesalers, ambulatory clinics, and other alternate-site providers such as outpatient centers, home healthcare services and long-term care facilities.
The company was established in 1984 and is headquartered in San Clemente, California. Its shares are listed on the NASDAQ under the ticker ICUI.
ICU Medical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48, in the Neutral zone, down 2.3 points over five sessions.
Down 2.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 21 | +4.3% | +6.1% | ||
| Accumulation | 170 | +1.0% | +1.8% | ||
| Neutral (current zone) | 348 | +0.4% | +2.7% | ||
| Distribution | 37 | −0.2% | +2.4% | ||
| Selling | 1 | Too few readings yet | |||
Average ICUI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
ICU Medical trades 21.3% above Gekko Fair Value of $147.73, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what ICU Medical shares are worth, recalculated every trading day.
$147.73
Gekko Fair Value, Nov 14, 2026
21.3% Overvalued
At the end of Aug 2026 the price was 5.7% below the estimate.
No open-market insider purchases were filed for ICU Medical, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ICUI in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ICUI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
ICU Medical has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds ICUI.
ICU Medical reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 18, 2027
Expected after the close, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $2.01 est $1.49 | $547.9M est $533.4M | +10.9% |
| May 7, 2026 | $1.97 est $1.75 | $525.8M est $520.6M | +5.7% |
| Feb 19, 2026 | $1.91 est $1.69 | $535.9M est $530.6M | +3.6% |
| Nov 6, 2025 | $2.03 est $1.43 | $537.0M est $511.5M | +10.0% |
| Aug 7, 2025 | $2.10 est $1.44 | $548.9M est $511.5M | −11.1% |
| May 8, 2025 | $1.72 est $1.28 | $604.7M est $603.7M | +2.8% |
| Feb 27, 2025 | $2.11 est $1.48 | $629.8M est $599.1M | −5.1% |
| Nov 12, 2024 | $1.59 est $1.25 | $589.1M est $574.6M | +25.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for ICU Medical is $194.25, +8.4% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 6 | Piper Sandler | $200 | +11.6% |
| Nov 6 | KeyBanc | $189 | +5.4% |
| Nov 5 | BTIG | $200 | +11.6% |
| Sep 23 | Piper Sandler | $195 | +8.8% |
| Sep 18 | Piper Sandler | $195 | +8.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, ICU Medical averaged +2.1% across the last 4 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 2 of 4 |
| Next 10 trading days | −1.4% | 1 of 4 |
| Next 15 trading days | −1.5% | 1 of 4 |
| Next 20 trading days | +2.1% | 3 of 4 |
| Next 30 trading days | +3.6% | 2 of 4 |
For scale, ICUI’s typical 20-trading-day move in either direction is about 6.9%.
ICU Medical’s market cap is $4.48B, with a P/E ratio of 74.2 and revenue of $2.18B over the last twelve months.
Coverage of ICU Medical this week reads positive: 4 positive, 3 neutral and 0 negative headlines.
ICU Medical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
ICU Medical’s market cap is $4.48B at the Nov 13, 2026 close of $179.27, with 25.01M shares outstanding. The shares trade on a P/E ratio of 74.2.
The consensus analyst 12-month price target for ICU Medical is $194.25, +8.4% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate ICU Medical is overvalued: the Nov 13, 2026 close of $179.27 is 21.3% above Gekko Fair Value of $147.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
ICU Medical is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of $2.15 per share on revenue of $559.3M. ICU Medical beat the earnings estimate in 8 of its last 8 reports, moving 9.3% on average across the report.
ICU Medical’s 52-week high is $192.85 and its 52-week low is $113.37; it closed at $179.27 on Nov 13, 2026, +28.8% over the past year. Over the last five years the shares peaked at $251.77 on Nov 19, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.